You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PAR-24-157: Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)

    Release Date: 02-29-2024Open Date: 03-05-2024 Due Dates: Multiple Close Date: 01-06-2027

    Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), works to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Translation is the process of turning observations in the ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PAS-22-197: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

    Release Date: 06-21-2022Open Date: 12-05-2022 Due Dates: Multiple Close Date: 09-06-2025

    Recommendations and milestones for Alzheimer's disease (AD) and AD-related dementias (ADRD) research from the National Alzheimer’s Project Act and, the 2015, 2018, 2019, and 2021 Alzheimer's Disease Research Summits present a wide range of research and development proposals which, if pursued, have the potential to reduce the human burden and healthcare costs associated with AD/ADRD. As part of ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PAS-22-196: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

    Release Date: 06-21-2022Open Date: 12-05-2022 Due Dates: Multiple Close Date: 09-08-2025

    Recommendations and milestones for Alzheimer's disease (AD) and AD-related dementias (ADRD) research from the National Alzheimer’s Project Act and the 2015, 2018, 2019, and 2021 Alzheimer's Disease Research Summits present a wide range of research and development proposals which, if pursued, have the potential to reduce the human burden and healthcare costs associated with AD/ADRD. As part of t ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PAR-24-098: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 01-22-2024Open Date: 02-22-2024 Due Dates: Multiple Close Date: 06-26-2026

    Background A biomarker is a defined characteristic that is measured as an indicator of a normal biological process, pathogenic process, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints. Because the measurement of the biomarker is integral to defining ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-24-063: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 11-01-2023Open Date: 01-09-2024 Due Dates: Multiple Close Date: 08-19-2026

    Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. However, before a new chemical entity can be tested in a clinical setting, it must undergo a process of chemical optimization to improve potency, selectivity, and drug-like properties, followed by pre-clinical safety testing to meet the standards set by the Food and Drug Admin ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-24-096: Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 01-22-2024Open Date: 02-22-2024 Due Dates: Multiple Close Date: 06-23-2026

    A biomarker is a defined characteristic that is measured as an indicator of a normal biological process, pathogenic process, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints. Because the measurement of the biomarker is integral to defining the biomarke ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-DA-23-021: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44- Clinical Trial Optional)

    Release Date: 03-28-2022Open Date: 07-15-2022 Due Dates: Multiple Close Date: 02-15-2025

    According to the Centers for Disease Control and Prevention (CDC), more than 100,000 deaths from overdose were reported from April 2020 to April 2021 alone. Data shows an increase in overdoses due to natural and semi-synthetic opioids, synthetic opioids, predominantly fentanyl, and psychostimulants, such as methamphetamine or cocaine. In fact, in the year ending in April 2021, fentanyl was the lea ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-DA-24-038: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)

    Release Date: 04-19-2023Open Date: 07-15-2023 Due Dates: Multiple Close Date: 02-15-2025

    According to the Centers for Disease Control and Prevention (CDC), more than 100,000 deaths from overdose were reported from April 2020 to April 2021 alone. Data shows an increase in overdoses due to natural and semi-synthetic opioids, synthetic opioids, predominantly fentanyl, and psychostimulants, such as methamphetamine or cocaine. In fact, in the year ending in April 2021, fentanyl was the lea ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. OSD244-P002: Development of novel 5G Open RAN (Radio Access Networks) xApp and rApp Applications Open Topic

    Release Date: 10-03-2023Open Date: 05-15-2024Due Date: 03-31-2025Close Date: 07-08-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): FutureG; Sustainment & Logistics OBJECTIVE: The Department of Defense (DoD) is seeking the development and demonstration of xApps and/or rApps focused on security and security related network measurement. DoD anticipates increasing reliance on 5G and FutureG OpenRAN networks, and needs tools and techniques that will enhance the security and resilience of ...

    SBIRPhase I/Phase IIDepartment of DefenseOffice of the Secretary of Defense
  10. RFA-DA-25-054: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning ( ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government